PRME
Price
$1.24
Change
-$0.00 (-0.00%)
Updated
Apr 17 closing price
Capitalization
162.64M
21 days until earnings call
TECH
Price
$48.10
Change
-$1.87 (-3.74%)
Updated
Apr 17 closing price
Capitalization
7.6B
12 days until earnings call
Ad is loading...

PRME vs TECH

Header iconPRME vs TECH Comparison
Open Charts PRME vs TECHBanner chart's image
Prime Medicine
Price$1.24
Change-$0.00 (-0.00%)
Volume$457.97K
Capitalization162.64M
Bio-Techne
Price$48.10
Change-$1.87 (-3.74%)
Volume$2.74M
Capitalization7.6B
PRME vs TECH Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. TECH commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and TECH is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (PRME: $1.24 vs. TECH: $48.10)
Brand notoriety: PRME and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 32% vs. TECH: 134%
Market capitalization -- PRME: $162.64M vs. TECH: $7.6B
PRME [@Biotechnology] is valued at $162.64M. TECH’s [@Biotechnology] market capitalization is $7.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 1 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • TECH’s FA Score: 1 green, 4 red.
According to our system of comparison, TECH is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 4 TA indicator(s) are bullish while TECH’s TA Score has 4 bullish TA indicator(s).

  • PRME’s TA Score: 4 bullish, 4 bearish.
  • TECH’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both PRME and TECH are a good buy in the short-term.

Price Growth

PRME (@Biotechnology) experienced а +5.98% price change this week, while TECH (@Biotechnology) price change was -2.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

PRME is expected to report earnings on May 09, 2025.

TECH is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TECH($7.6B) has a higher market cap than PRME($163M). TECH YTD gains are higher at: -33.142 vs. PRME (-57.534). TECH has higher annual earnings (EBITDA): 307M vs. PRME (-196.34M). PRME has more cash in the bank: 190M vs. TECH (178M). PRME has less debt than TECH: PRME (40.8M) vs TECH (395M). TECH has higher revenues than PRME: TECH (1.2B) vs PRME (2.98M).
PRMETECHPRME / TECH
Capitalization163M7.6B2%
EBITDA-196.34M307M-64%
Gain YTD-57.534-33.142174%
P/E RatioN/A49.08-
Revenue2.98M1.2B0%
Total Cash190M178M107%
Total Debt40.8M395M10%
FUNDAMENTALS RATINGS
PRME vs TECH: Fundamental Ratings
PRME
TECH
OUTLOOK RATING
1..100
778
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
3
Undervalued
PROFIT vs RISK RATING
1..100
10089
SMR RATING
1..100
9678
PRICE GROWTH RATING
1..100
9665
P/E GROWTH RATING
1..100
10036
SEASONALITY SCORE
1..100
5875

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for PRME (38) in the null industry. This means that TECH’s stock grew somewhat faster than PRME’s over the last 12 months.

TECH's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that TECH’s stock grew similarly to PRME’s over the last 12 months.

TECH's SMR Rating (78) in the Biotechnology industry is in the same range as PRME (96) in the null industry. This means that TECH’s stock grew similarly to PRME’s over the last 12 months.

TECH's Price Growth Rating (65) in the Biotechnology industry is in the same range as PRME (96) in the null industry. This means that TECH’s stock grew similarly to PRME’s over the last 12 months.

TECH's P/E Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for PRME (100) in the null industry. This means that TECH’s stock grew somewhat faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMETECH
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
66%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
69%
Advances
ODDS (%)
Bullish Trend 30 days ago
78%
Bullish Trend 5 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 1 day ago
72%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
68%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
73%
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
THOFX36.960.30
+0.82%
Thornburg Global Opportunities R5
RYSPX79.87N/A
N/A
Rydex S&P 500 H
HAONX13.49N/A
N/A
Harbor International Core Investor
LAAGX13.68N/A
N/A
Lord Abbett International Growth A
FEYCX24.22N/A
N/A
Fidelity Advisor Asset Manager 85% C

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
N/A
CRSP - PRME
63%
Loosely correlated
-0.03%
RXRX - PRME
60%
Loosely correlated
+3.38%
BEAM - PRME
58%
Loosely correlated
+2.29%
NTLA - PRME
57%
Loosely correlated
+5.39%
ABCL - PRME
54%
Loosely correlated
+1.26%
More

TECH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TECH has been loosely correlated with AXON. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if TECH jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TECH
1D Price
Change %
TECH100%
-3.75%
AXON - TECH
61%
Loosely correlated
-2.15%
ADPT - TECH
47%
Loosely correlated
-2.14%
XNCR - TECH
46%
Loosely correlated
+1.89%
NTLA - TECH
45%
Loosely correlated
+5.39%
PRME - TECH
45%
Loosely correlated
N/A
More